Trial · NCT02477332
Results by group66
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 66
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With Complete Hives Response (HSS7=0) | QGE031 24 mg s.c. q4w | 30.2 | 95% Confidence Interval 17.2 to 46.1 | Percentage of participants | |
| Percentage of Participants With Complete Hives Response (HSS7=0) | QGE031 72 mg s.c. q4w | 51.2 | 95% Confidence Interval 40.0 to 62.3 | Percentage of participants | |
| Percentage of Participants With Complete Hives Response (HSS7=0) | QGE031 240 mg s.c. q4w | 42.4 | 95% Confidence Interval 31.7 to 53.6 | Percentage of participants | |
| Percentage of Participants With Complete Hives Response (HSS7=0) | Omalizumab 300 mg s.c. q4w | 25.9 | 95% Confidence Interval 17.0 to 36.5 | Percentage of participants | |
| Percentage of Participants With Complete Hives Response (HSS7=0) | Placebo s.c. q4w | 0 | 95% Confidence Interval 0.0 to 8.2 | Percentage of participants | |
| Percentage of Participants With Complete Hives Response (HSS7=0) | QGE031 120 mg s.c. s.d. | 19.0 | 95% Confidence Interval 8.6 to 34.1 | Percentage of participants | |
| Complete Hives Response (HSS7=0) Rate at Week 12 Measured Over 7 Days | QGE031 24 mg s.c. q4w | 13 | Particpants | ||
| Complete Hives Response (HSS7=0) Rate at Week 12 Measured Over 7 Days | QGE031 72 mg s.c. q4w | 43 | Particpants | ||
| Complete Hives Response (HSS7=0) Rate at Week 12 Measured Over 7 Days | QGE031 240 mg s.c. q4w | 36 | Particpants | ||
| Complete Hives Response (HSS7=0) Rate at Week 12 Measured Over 7 Days | Omalizumab 300 mg s.c. q4w | 22 | Particpants | ||
| Complete Hives Response (HSS7=0) Rate at Week 12 Measured Over 7 Days | Placebo | 0 | Particpants | ||
| Change From Baseline in Hives Severity Score (HSS7) at Week 12 Measured Over 7 Days | QGE031 24 mg s.c. q4w | -9.75 | 95% Confidence Interval -15.75 to -2.50 | Score on a scale | |
| Change From Baseline in Hives Severity Score (HSS7) at Week 12 Measured Over 7 Days | QGE031 72 mg s.c. q4w | -15.50 | 95% Confidence Interval -20.00 to -6.00 | Score on a scale | |
| Change From Baseline in Hives Severity Score (HSS7) at Week 12 Measured Over 7 Days | QGE031 240 mg s.c. q4w | -13.50 | 95% Confidence Interval -19.00 to -9.00 | Score on a scale | |
| Change From Baseline in Hives Severity Score (HSS7) at Week 12 Measured Over 7 Days | Omalizumab 300 mg s.c. q4w | -11.00 | 95% Confidence Interval -16.50 to -4.50 | Score on a scale | |
| Change From Baseline in Hives Severity Score (HSS7) at Week 12 Measured Over 7 Days | Placebo | -6.50 | 95% Confidence Interval -13.00 to -2.33 | Score on a scale | |
| HSS7=0 Response: at Week 20 Measured Over 7 Days | QGE031 24 mg s.c. q4w | 11 | Participants | ||
| HSS7=0 Response: at Week 20 Measured Over 7 Days | QGE031 72 mg s.c. q4w | 43 | Participants | ||
| HSS7=0 Response: at Week 20 Measured Over 7 Days | QGE031 240 mg s.c. q4w | 38 | Participants | ||
| HSS7=0 Response: at Week 20 Measured Over 7 Days | Omalizumab 300 mg s.c. q4w | 29 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02477332/results